XENERA Trademark

Trademark Overview

On Saturday, February 17, 2018, a trademark application was filed for XENERA with the United States Patent and Trademark Office. The USPTO has given the XENERA trademark a serial number of 79229690. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Thursday, June 5, 2025. This trademark is owned by Boehringer Ingelheim International GmbH. The XENERA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research in the field of oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
xenera

General Information

Serial Number79229690
Word MarkXENERA
Filing DateSaturday, February 17, 2018
Status706 - SECTION 71 ACCEPTED
Status DateThursday, June 5, 2025
Registration Number5682654
Registration DateTuesday, February 26, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2018

Trademark Statements

Goods and ServicesMedical and scientific research in the field of oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, April 6, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBoehringer Ingelheim International GmbH
Party Type30 - Original Registrant
Legal Entity Type27 - NOT AVAILABLE
AddressIngelheim 55218
DE
Party NameBoehringer Ingelheim International GmbH
Party Type20 - Owner at Publication
Legal Entity Type27 - NOT AVAILABLE
AddressDE
Party NameBoehringer Ingelheim International GmbH
Party Type10 - Original Applicant
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Trademark Events

Event DateEvent Description
Wednesday, April 11, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, April 13, 2018REFUSAL PROCESSED BY MPU
Thursday, April 5, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, April 6, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 6, 2018ASSIGNED TO EXAMINER
Tuesday, April 10, 2018APPLICATION FILING RECEIPT MAILED
Tuesday, April 10, 2018NON-FINAL ACTION WRITTEN
Wednesday, November 21, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, April 13, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 4, 2018REFUSAL PROCESSED BY IB
Monday, October 15, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 15, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 16, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 18, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 1, 2018ASSIGNED TO LIE
Wednesday, November 21, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 21, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 11, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sunday, May 26, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, December 8, 2018NOTIFICATION PROCESSED BY IB
Tuesday, December 11, 2018PUBLISHED FOR OPPOSITION
Tuesday, February 26, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, February 12, 2025TEAS SECTION 71 RECEIVED
Thursday, June 20, 2019FINAL DISPOSITION PROCESSED
Thursday, June 20, 2019FINAL DISPOSITION NOTICE SENT TO IB
Friday, July 12, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, February 26, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Monday, June 2, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, June 5, 2025REGISTERED-SEC.71 ACCEPTED
Thursday, June 5, 2025NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

Related Keywords

xenera medical research field scientific clinical trials pharmaceuticals oncology providing information